Sinovac Life Sciences Co., Ltd.

This early-stage study tested a new vaccine designed to protect against 13 types of pneumococcal bacteria that can cause pneumonia and other serious infections. Researchers enrolled 310 healthy participants ranging from infants as young as 6 weeks to adults up to 49 years old to …

This study tested the safety and immune response of a new oral vaccine designed to protect against rotavirus, a common cause of severe diarrhea in infants and young children. The trial involved 100 healthy participants, including adults, children, and infants, who received either…

This study tested a new 24-strain pneumococcal vaccine (PCV24) in 119 healthy children aged 2-17 years to see if it is safe and triggers a strong immune response. It was an early-phase trial comparing the new vaccine against an existing 13-strain vaccine in younger children. The …